{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:51:31Z","timestamp":1790898691992,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>NOTCH1 alterations have been associated with chronic lymphocytic leukemia (CLL), but the molecular mechanisms underlying NOTCH1 activation in CLL cells are not completely understood. Here, we show that GSK3\u03b2 downregulates the constitutive levels of the active NOTCH1 intracellular domain (N1-ICD) in CLL cells. Indeed, GSK3\u03b2 silencing by small interfering RNA increases N1-ICD levels, whereas expression of an active GSK3\u03b2 mutant reduces them. Additionally, the GSK3\u03b2 inhibitor SB216763 enhances N1-ICD stability at a concentration at which it also increases CLL cell viability. We also show that N1-ICD is physically associated with GSK3\u03b2 in CLL cells. SB216763 reduces GSK3\u03b2\/N1-ICD interactions and the levels of ubiquitinated N1-ICD, indicating a reduction in N1-ICD proteasomal degradation when GSK3\u03b2 is less active. We then modulated the activity of two upstream regulators of GSK3\u03b2 and examined the impact on N1-ICD levels and CLL cell viability. Specifically, we inhibited AKT that is a negative regulator of GSK3\u03b2 and is constitutively active in CLL cells. Furthermore, we activated the protein phosphatase 2\u2009A (PP2A) that is a positive regulator of GSK3\u03b2, and has an impaired activity in CLL. Results show that either AKT inhibition or PP2A activation reduce N1-ICD expression and CLL cell viability in vitro, through mechanisms mediated by GSK3\u03b2 activity. Notably, for PP2A activation, we used the highly specific activator DT-061, that also reduces leukemic burden in peripheral blood, spleen and bone marrow in the E<jats:italic>\u00b5<\/jats:italic>-TCL1 adoptive transfer model of CLL, with a concomitant decrease in N1-ICD expression. Overall, we identify in GSK3\u03b2 a key component of the network regulating N1-ICD stability in CLL, and in AKT and PP2A new druggable targets for disrupting NOTCH1 signaling with therapeutic potential.<\/jats:p>","DOI":"10.1038\/s41419-022-05178-w","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T17:04:03Z","timestamp":1662051843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["GSK3\u03b2 is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL"],"prefix":"10.1038","volume":"13","author":[{"given":"Filomena","family":"De Falco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rompietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Sorcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Scialdone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Del Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Maria","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estev\u00e3o Carlos","family":"Silva Barcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Dorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Di Ianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-9098","authenticated-orcid":false,"given":"Isabella","family":"Screpanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-123X","authenticated-orcid":false,"given":"Emanuela","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"5178_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N. Engl J Med 2005;352:804\u201315.","journal-title":"N. Engl J Med"},{"key":"5178_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.8","volume":"16","author":"G Fabbri","year":"2016","unstructured":"Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer 2016;16:145\u201362.","journal-title":"Nat Rev Cancer"},{"key":"5178_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol 2019;16:684\u2013701.","journal-title":"Nat Rev Clin Oncol"},{"key":"5178_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fonc.2018.00229","volume":"8","author":"E Rosati","year":"2018","unstructured":"Rosati E, Baldoni S, De Falco F, Del Papa B, Dorillo E, Rompietti C, et al. NOTCH1 aberrations in chronic lymphocytic leukemia. Front Oncol 2018;8:229.","journal-title":"Front Oncol"},{"key":"5178_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","volume":"113","author":"E Rosati","year":"2009","unstructured":"Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113:856\u201365.","journal-title":"Blood"},{"key":"5178_CR6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/ijc.27863","volume":"132","author":"E Rosati","year":"2013","unstructured":"Rosati E, Sabatini R, De Falco F, Del Papa B, Falzetti F, Di Ianni M, et al. \u03b3-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int J Cancer. 2013;132:1940\u201353.","journal-title":"Int J Cancer"},{"key":"5178_CR7","doi-asserted-by":"publisher","first-page":"16559","DOI":"10.18632\/oncotarget.4116","volume":"6","author":"F De Falco","year":"2015","unstructured":"De Falco F, Sabatini R, Del Papa B, Falzetti F, Di Ianni M, Sportoletti P, et al. Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. Oncotarget. 2015;6:16559\u201372.","journal-title":"Oncotarget"},{"key":"5178_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fonc.2018.00105","volume":"8","author":"M Di Ianni","year":"2018","unstructured":"Di Ianni M, Baldoni S, Del Papa B, Aureli P, Dorillo E, De Falco F, et al. NOTCH1 is aberrantly activated in chronic lymphocytic leukemia hematopoietic stem cells. Front Oncol 2018;8:105.","journal-title":"Front Oncol"},{"key":"5178_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-2141.2009.07816.x","volume":"146","author":"M Di Ianni","year":"2009","unstructured":"Di Ianni M, Baldoni S, Rosati E, Ciurnelli R, Cavalli L, Martelli MF, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol 2009;146:689\u201391.","journal-title":"Br J Haematol"},{"key":"5178_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1365-2141.2010.08368.x","volume":"151","author":"P Sportoletti","year":"2010","unstructured":"Sportoletti P, Baldoni S, Cavalli L, Del Papa B, Bonifacio E, Ciurnelli R, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010;151:404\u20136.","journal-title":"Br J Haematol"},{"key":"5178_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ord\u00f3\u00f1ez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101\u20135.","journal-title":"Nature"},{"key":"5178_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012;119:521\u20139.","journal-title":"Blood"},{"key":"5178_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/leu.2013.289","volume":"28","author":"P Sportoletti","year":"2014","unstructured":"Sportoletti P, Baldoni S, Del Papa B, Aureli P, Dorillo E, Ruggeri L, et al. A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia. Leukemia. 2014;28:436\u20139.","journal-title":"Leukemia"},{"key":"5178_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/leu.2013.319","volume":"28","author":"F Arruga","year":"2014","unstructured":"Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia. 2014;28:1060\u201370.","journal-title":"Leukemia"},{"key":"5178_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/leu.2014.329","volume":"29","author":"F De Falco","year":"2015","unstructured":"De Falco F, Sabatini R, Falzetti F, Di Ianni M, Sportoletti P, Baldoni S, et al. Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. Leukemia. 2015;29:994\u20138.","journal-title":"Leukemia"},{"key":"5178_CR16","doi-asserted-by":"publisher","first-page":"E2911","DOI":"10.1073\/pnas.1702564114","volume":"114","author":"G Fabbri","year":"2017","unstructured":"Fabbri G, Holmes AB, Viganotti M, Scuoppo C, Belver L, Herranz D, et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2017;114:E2911\u2013E2919.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5178_CR17","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1182\/blood.2020006701","volume":"137","author":"D Tardivon","year":"2021","unstructured":"Tardivon D, Antoszewski M, Zangger N, Nkosi M, Sordet-Dessimoz J, Hendriks R, et al. Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia. Blood. 2021;137:3079\u201392.","journal-title":"Blood"},{"key":"5178_CR18","doi-asserted-by":"publisher","first-page":"e67306","DOI":"10.1371\/journal.pone.0067306","volume":"8","author":"MJ Kluk","year":"2013","unstructured":"Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS One. 2013;8:e67306.","journal-title":"PLoS One"},{"key":"5178_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1185-6","volume":"9","author":"F De Falco","year":"2018","unstructured":"De Falco F, Del Papa B, Baldoni S, Sabatini R, Falzetti F, Di Ianni M, et al. IL-4-dependent Jagged1 expression\/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. Cell Death Dis. 2018;9:1160.","journal-title":"Cell Death Dis"},{"key":"5178_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41375-019-0571-0","volume":"34","author":"F Arruga","year":"2020","unstructured":"Arruga F, Bracciam\u00e0 V, Vitale N, Vaisitti T, Gizzi K, Yeomans A, et al. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter\u2019s syndrome: therapeutic implications. Leukemia. 2020;34:462\u201377.","journal-title":"Leukemia"},{"key":"5178_CR21","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-19-1009","volume":"25","author":"B Del Papa","year":"2019","unstructured":"Del Papa B, Baldoni S, Dorillo E, De Falco F, Rompietti C, Cecchini D, et al. Decreased NOTCH1 activation correlates with response to ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 2019;25:7540\u201353.","journal-title":"Clin Cancer Res"},{"key":"5178_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/35096075","volume":"2","author":"P Cohen","year":"2001","unstructured":"Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769\u201376.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5178_CR23","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00018-007-7045-7","volume":"64","author":"JE Forde","year":"2007","unstructured":"Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Life Mol Sci 2007;64:1930\u201344.","journal-title":"Cell Life Mol Sci"},{"key":"5178_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/bs.ctdb.2016.11.011","volume":"123","author":"P Patel","year":"2017","unstructured":"Patel P, Woodgett JR. Glycogen synthase kinase 3: a kinase for all pathways? Curr Top Dev Biol 2017;123:277\u2013302.","journal-title":"Curr Top Dev Biol"},{"key":"5178_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785\u20139.","journal-title":"Nature"},{"key":"5178_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","volume":"7","author":"S Frame","year":"2001","unstructured":"Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001;7:1321\u20137.","journal-title":"Mol Cell"},{"key":"5178_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jbior.2017.06.003","volume":"65","author":"MA Hermida","year":"2017","unstructured":"Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K\/AKT\/mTOR signalling network. Adv Biol Regul 2017;65:5\u201315. https:\/\/doi.org\/10.1016\/j.jbior.2017.06.003","journal-title":"Adv Biol Regul"},{"key":"5178_CR28","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","volume":"14","author":"D Perrotti","year":"2013","unstructured":"Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013;14:e229\u2013238.","journal-title":"Lancet Oncol"},{"key":"5178_CR29","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood-2011-04-351072","volume":"118","author":"DJ Christensen","year":"2011","unstructured":"Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood. 2011;118:4150\u20138.","journal-title":"Blood"},{"key":"5178_CR30","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1182\/blood-2014-12-619155","volume":"125","author":"F Zonta","year":"2015","unstructured":"Zonta F, Pagano MA, Trentin L, Tibaldi E, Frezzato F, Trimarco V, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. 2015;125:3747\u201355.","journal-title":"Blood"},{"key":"5178_CR31","first-page":"147","volume":"1114","author":"SE Plyte","year":"1992","unstructured":"Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1992;1114:147\u201362.","journal-title":"Biochim Biophys Acta"},{"key":"5178_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jbior.2013.09.013","volume":"54","author":"JA McCubrey","year":"2014","unstructured":"McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Basecke J, et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014;54:176\u201396.","journal-title":"Adv Biol Regul"},{"key":"5178_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/blood.2018874560","volume":"134","author":"X Wu","year":"2019","unstructured":"Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019;134:363\u201373.","journal-title":"Blood"},{"key":"5178_CR34","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0960-9822(02)00888-6","volume":"12","author":"DR Foltz","year":"2002","unstructured":"Foltz DR, Santiago MC, Berechid BE, Nye JS. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 2002;12:1006\u201311.","journal-title":"Curr Biol"},{"key":"5178_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00395-011-0189-5","volume":"106","author":"S Guha","year":"2011","unstructured":"Guha S, Cullen JP, Morrow D, Lally C, Walls D, Redmond EM, et al. Glycogen synthase kinase 3 beta positively regulates Notch signaling in vascular smooth muscle cells: role in cell proliferation and survival. Basic Res Cardiol 2011;106:773\u201385.","journal-title":"Basic Res Cardiol"},{"key":"5178_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbrc.2012.05.111","volume":"423","author":"X Han","year":"2012","unstructured":"Han X, Ju JH, Shin I. Glycogen synthase kinase 3-\u03b2 phosphorylates novel S\/T-P-S\/T domains in Notch1 intracellular domain and induces its nuclear localization. Biochem Biophys Res Commun 2012;423:282\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"5178_CR37","doi-asserted-by":"publisher","first-page":"32227","DOI":"10.1074\/jbc.M304001200","volume":"278","author":"L Espinosa","year":"2003","unstructured":"Espinosa L, Ingl\u00e9s-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003;278:32227\u2013335.","journal-title":"J Biol Chem"},{"key":"5178_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-7-10","volume":"7","author":"G McKenzie","year":"2006","unstructured":"McKenzie G, Ward G, Stallwood Y, Briend E, Papadia S, Lennard A, et al. Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals. BMC Cell Biol. 2006;7:10.","journal-title":"BMC Cell Biol"},{"key":"5178_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10059-009-0001-7","volume":"27","author":"YH Jin","year":"2009","unstructured":"Jin YH, Kim H, Oh M, Ki H, Kim K. Regulation of Notch1\/NICD and Hes1 expressions by GSK-3alpha\/beta. Mol Cells 2009;27:15\u201319.","journal-title":"Mol Cells"},{"key":"5178_CR40","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/nn.2408","volume":"12","author":"WY Kim","year":"2009","unstructured":"Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 2009;12:1390\u20137.","journal-title":"Nat Neurosci"},{"key":"5178_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1091\/mbc.E17-07-0474","volume":"29","author":"L Zheng","year":"2018","unstructured":"Zheng L, Conner SD. Glycogen synthase kinase 3\u03b2 inhibition enhances Notch1 recycling. Mol Biol Cell 2018;29:389\u201395.","journal-title":"Mol Biol Cell"},{"key":"5178_CR42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-5521(00)00025-9","volume":"7","author":"MP Coghlan","year":"2000","unstructured":"Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793\u2013803.","journal-title":"Chem Biol"},{"key":"5178_CR43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1042\/bj3030701","volume":"303","author":"V Stambolic","year":"1994","unstructured":"Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3\u03b2 in intact cells via serine 9 phosphorylation. Biochem J 1994;303:701\u20134.","journal-title":"Biochem J"},{"key":"5178_CR44","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1073\/pnas.0308648100","volume":"101","author":"D Lu","year":"2004","unstructured":"Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2004;101:3118\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5178_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","volume":"24","author":"JA Burger","year":"2014","unstructured":"Burger JA, Gribben JB. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Rev Semin Cancer Biol. 2014;24:71\u201381.","journal-title":"Rev Semin Cancer Biol"},{"key":"5178_CR46","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4049\/jimmunol.163.4.1894","volume":"163","author":"MR Gold","year":"1999","unstructured":"Gold MR, Scheid MP, Santos L, Dang-Lawson M, Roth RA, Matsuuchi L, et al. The B cell antigen receptor activates the Akt (protein kinase B)\/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase. J Immunol 1999;163:1894\u2013905.","journal-title":"J Immunol"},{"key":"5178_CR47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2009.010272","volume":"95","author":"J Zhuang","year":"2010","unstructured":"Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, et al. Akt is activated in chronic-lymphocytic-leukemia cells and delivers a pro-survival signal: therapeutic potential of Akt inhibition. Haematologica. 2010;95:110\u20138.","journal-title":"Haematologica"},{"key":"5178_CR48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","volume":"111","author":"PG Longo","year":"2008","unstructured":"Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846\u201355.","journal-title":"Blood"},{"key":"5178_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.2020005734","volume":"137","author":"V Kohlhaas","year":"2021","unstructured":"Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, et al. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021;137:646\u201360.","journal-title":"Blood"},{"key":"5178_CR50","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3324\/haematol.2008.004028","volume":"94","author":"M de Frias","year":"2009","unstructured":"de Frias M, Iglesias-Serret D, Cosialls AM, Coll-Mulet L, Santidri\u00e1n AF, Gonz\u00e1lez-Giron\u00e8s DM, et al. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009;94:1698\u2013707.","journal-title":"Haematologica"},{"key":"5178_CR51","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u2013W743.","journal-title":"Nucleic Acids Res"},{"key":"5178_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2006-10-053884","volume":"111","author":"Q Liu","year":"2008","unstructured":"Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia\/lymphoma. Blood. 2008;111:275\u201384.","journal-title":"Blood"},{"key":"5178_CR53","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41375-018-0288-5","volume":"33","author":"MA Pagano","year":"2019","unstructured":"Pagano MA, Tibaldi E, Molino P, Frezzato F, Trimarco V, Facco M, et al. Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. Leukemia. 2019;33:1148\u201360.","journal-title":"Leukemia"},{"key":"5178_CR54","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2020.03.038","volume":"181","author":"D Leonard","year":"2020","unstructured":"Leonard D, Huang W, Izadmehr S, O\u2019Connor CM, Wiredja DD, Wang Z, et al. Selective PP2A enhancement through biased heterotrimer stabilization. Cell. 2020;181:688\u2013701.","journal-title":"Cell"},{"key":"5178_CR55","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1172\/JCI89548","volume":"127","author":"J Sangodkar","year":"2017","unstructured":"Sangodkar J, Perl A, Tohm\u00e8 R, Kiselar J, Kastrinsky DB, Zaware N, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest 2017;127:2081\u201390.","journal-title":"J Clin Invest"},{"key":"5178_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0021-9258(17)49933-9","volume":"295","author":"CC Farrington","year":"2020","unstructured":"Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, et al. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. J Biol Chem 2020;295:757\u201370.","journal-title":"J Biol Chem"},{"key":"5178_CR57","doi-asserted-by":"publisher","first-page":"e125693","DOI":"10.1172\/jci.insight.125693","volume":"4","author":"R Tohm\u00e9","year":"2019","unstructured":"Tohm\u00e9 R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, et al. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. JCI Insight. 2019;4:e125693.","journal-title":"JCI Insight"},{"key":"5178_CR58","doi-asserted-by":"publisher","first-page":"eaaq1093.","DOI":"10.1126\/scitranslmed.aaq1093","volume":"10","author":"O Kauko","year":"2018","unstructured":"Kauko O, O\u2019Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med 2018;10:eaaq1093.","journal-title":"Sci Transl Med"},{"key":"5178_CR59","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/onc.2009.179","volume":"28","author":"AD Baudot","year":"2009","unstructured":"Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene. 2009;28:3261\u201373.","journal-title":"Oncogene"},{"key":"5178_CR60","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1182\/blood-2014-05-574830","volume":"124","author":"D El-Gamal","year":"2014","unstructured":"El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, et al. PKC-\u03b2 as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood. 2014;124:1481\u201391.","journal-title":"Blood"},{"key":"5178_CR61","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood.2020010187","volume":"137","author":"A Iannello","year":"2021","unstructured":"Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137:3378\u201389.","journal-title":"Blood"},{"key":"5178_CR62","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2006-12-060947","volume":"110","author":"AV Ougolkov","year":"2007","unstructured":"Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007;110:735\u201342.","journal-title":"Blood"},{"key":"5178_CR63","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1084\/jem.20131448","volume":"210","author":"G Fabbri","year":"2013","unstructured":"Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013;210:2273\u201388.","journal-title":"J Exp Med"},{"key":"5178_CR64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/0008-5472.CAN-18-0717","volume":"79","author":"BL Allen-Petersen","year":"2019","unstructured":"Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, et al. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79:209\u201319.","journal-title":"Cancer Res."},{"key":"5178_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"key":"5178_CR66","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"5178_CR67","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","volume":"40","author":"JL Binet","year":"1977","unstructured":"Binet JL, Leporrier M, Dighiero G, Charron D, D\u2019Athis P, Vaugier G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855\u201364.","journal-title":"Cancer"},{"key":"5178_CR68","doi-asserted-by":"publisher","first-page":"668573","DOI":"10.3389\/fonc.2021.668573","volume":"11","author":"S Baldoni","year":"2021","unstructured":"Baldoni S, Del Papa B, De Falco F, Dorillo E, Sorrentino C, Rompietti C, et al. NOTCH1 activation negatively impacts on chronic lymphocytic leukemia outcome and is not correlated to the NOTCH1 and IGHV mutational status. Front Oncol 2021;11:668573.","journal-title":"Front Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05178-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:34:58Z","timestamp":1676666098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05178-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["5178"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05178-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"755"}}